High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol

Human Reproduction

Volumn 28, Issue 2, 2013, Pages 442-452

  Fatemi, Human M ^a   Doody, Kevin ^b   Griesinger, Georg ^c   Witjes, Han ^d   Mannaerts, Bernadette ^d  

^a CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^b Center for Assisted Reproduction   (United States)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d MSD   (Netherlands)

Author keywords

corifollitropin alfa; GnRH antagonist; high ovarian response; pregnancy outcome

Indexed keywords

CORIFOLLITROPIN ALFA; ESTRADIOL; GANIRELIX; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ARTICLE; BIRTH RATE; BODY WEIGHT; CLINICAL PROTOCOL; CONTROLLED STUDY; CRYOPRESERVATION; DRUG RESPONSE; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HORMONAL THERAPY; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; MAJOR CLINICAL STUDY; MATERNAL AGE; MENSTRUAL CYCLE; OOCYTE; OOCYTE RETRIEVAL; OVULATION INDUCTION; PREGNANCY RATE; PROGESTERONE BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 84872510542     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/des389     Document Type: Article

References (26)

1. Al-Azemi M, Kyrou D, Kolibianakis EM, Humaidan P, Van VI, Devroey P, Fatemi HM. Elevated progesterone during ovarian stimulation for IVF. Reprod Biomed Online 2012;24: 381-388.
2. Baart EB, Martini E, Eijkemans MJ, Van Opstal D, Beckers NGM, Verhoeff A, Macklon NS, Fauser BCJM. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod 2007;22: 980-988.
3. Boostanfar R, Mannaerts B, Pang S, Fernandez M, Witjes H, Devroey P., Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertil Steril 2012;97: 1351-1358.
4. Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Jenkins J, Pellicer A. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod 2010;25: 2092-2100.
5. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006;12: 685-718.
6. Broer SL, Dolleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJM. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta analysis. Hum Reprod Update 2011;17: 46-54.
7. Devroey P, Bourgain C, Macklon NS, Fauser BC. Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab 2004;15: 84-90.
8. Devroey P, Boonstanfar R, Koper NP, Mannaerts BMJL, IJzerman-boon PC, Fauser BCJM., On Behalf of the Engage Investigators. Double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009;24: 3063-3072.
9. Doody KJ, Devroey P, Leader A, Witjes H, Mannaerts BM. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: Part I, corifollitropin alfa. Reprod Biomed Online 2011;23: 449-456.
10. Fauser BC, Nargund G, Andersen AN, Norman R, Tarlatzis B, Boivin J, Ledger W. Mild ovarian stimulation for IVF: 10 years later. Hum Reprod 2010a;25: 2678-2684.
11. Fauser BCJM, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BMJL. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during controlled ovarian stimulation for in vitro fertilisation. Reprod Biomed Online 2010b; 21: 593-601.
12. Heijnen EM, Eijkemans MJ, De KC, Polinder S, Beckers NG, Klinkert ER, Broekmans FJ, Passchier J, Te Velde ER, Macklon NS et al. A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet 2007;369: 743-749.
13. Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003; 88: 166-173.
14. Kok JD, Looman CW,Weima SM, Te Velde ER. A high number of oocytes obtained after ovarian hyperstimulation for in vitro fertilization or intracytoplasmic sperm injection is not associated with decreased pregnancy outcome. Fertil Steril 2006;85: 918-924.
15. Kolibianakis EM, Venetis CA, Bontis J, Tarlatzis BC. Significantly lower pregnancy rates in the presence of progesterone elevation in patients treated with GnRH antagonists and gonadotrophins: a systematic review and meta-analysis. Curr Pharm Biotechnol 2012;13: 464-470.
16. Kyrou D, Popovic-Todorovic B, Fatemi HM, Bourgain C, Haentjens P, Van LL, Devroey P. Does the estradiol level on the day of human chorionic gonadotrophin administration have an impact on pregnancy rates in patients treated with rec-FSH/GnRH antagonist? Hum Reprod 2009;24: 2902-2909.
17. Kyrou D, Kolibianakis EM, Fatemi HM, Camus M, Tournaye H, Tarlatzis BC, Devroey P. High exposure to progesterone between the end of menstruation and the day of triggering final oocyte maturation is associated with a decreased probability of pregnancy in patients treated by in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril 2011;96: 884-888.
18. Nyboe Andersen A, Witjes H, Gordon K, Mannaerts B. Predictive factors of ovarian response to controlled ovarian stimulation in a rFSH/GnRH antagonist protocol with and without oral contraceptive pretreatment. Hum Reprod 2011;26: 3413-3423.
19. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van SA, Devroey P. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropinreleasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85: 112-120.
20. Sterrenburg M, Blockeel C, Eijkemans M, Broer S, Macklon F, Broekmans F, Devroey P, Fauser B. Comparison between start of ovarian stimulation on cycle day 2 versus cycle day 5 with GnRH antagonist in IVF treatment: a randomized controlled trial. Hum Reprod 2011;26: i46-i48.
21. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod 2011;26: 1768-1774.
22. Tarlatzis BC, Greisinger G, Leader A, Rombouts L, Ijzerman-Boon PC, Mannaerts BMJL. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. Reprod Biomed Online 2012;24: 410-419.
23. van der Gaast MH, Eijkemans MJ, van der Net JB, de Boer EJ, Burger CW, van Leeuwen FE, Fauser BC, Macklon NS. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod Biomed Online 2006; 13: 476-480.
24. Verberg MF, Eijkemans MJC, Macklon NS, Heijnen EMEW, Baart EB, Hohmann FP, Fauser BCJM, Broekmans FJ. The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta analysis. Hum Reprod Update 2009a;15: 5-12.
25. Verberg MF, Macklon NS, Nargund G, Frydman R, Devroey P, Broekmans FJ, Fauser BCJM. Mild ovarian stimulation for IVF. Hum Reprod Update 2009b;15: 13-29.
26. Yding AC, Bungum L, Nyboe Andersen A, Humaidan P. Preovulatory progesterone concentration associates significantly to follicle number and LH concentration but not to pregnancy rate. Reprod Biomed Online 2011;23: 187-195.